Antheia Partners with TAPI to Advance Biomanufacturing of Drug Ingredients

Antheia, a biomanufacturing company specializing in synthetic biology, has announced a strategic partnership with TAPI, Teva Pharmaceutical Industries' active pharmaceutical ingredient (API) and contract manufacturing arm. This collaboration aims to accelerate the commercialization of Antheia's pipeline of biosynthetic drug ingredients and key starting materials (KSMs).

Expanding Production Capabilities

The alliance between Antheia and TAPI will combine Antheia's innovative biosynthesis platform with TAPI's extensive fermentation expertise and European manufacturing infrastructure. This partnership is expected to enable Antheia to scale up production of its APIs and KSMs to meet market demands.

Zack McGahey, Antheia's Chief Operating Officer, emphasized the importance of this collaboration, stating, "As demand for Antheia's products continues to grow, our ability to both increase the scale of existing products and accelerate future product launches is critical." McGahey added that TAPI's century-long experience in API manufacturing and state-of-the-art infrastructure would be instrumental in meeting growing customer demand and executing Antheia's commercialization strategy.

Antheia's Recent Developments

This partnership comes on the heels of several significant milestones for Antheia. In 2024, the company successfully completed its first commercialization project, delivering a full-scale order of thebaine, a crucial KSM used in the production of post-surgery pain medications, overdose rescue drugs, and addiction treatments. Thebaine is notably a key component of the overdose rescue medication Narcan.

Furthermore, Antheia secured $56 million in Series C funding in June 2025, which the company plans to use for expanding its U.S. production capabilities and launching new innovation programs in Singapore. These developments underscore Antheia's commitment to addressing drug shortages through rapid, on-demand production of pharmaceutical building blocks using advanced synthesis and fermentation technologies.

TAPI's Strategic Position

TAPI, established in 1935, brings considerable expertise to this partnership. With a portfolio of over 350 APIs and operations across 13 global sites, TAPI is a major player in the pharmaceutical ingredients sector. However, the company's future ownership remains uncertain, as Teva Pharmaceutical Industries has expressed intentions to divest the unit as part of its restructuring strategy.

Despite terminating exclusive talks with a potential buyer in Q3 2025, Teva maintains its "strategic intention to divest" TAPI. The company cites recent geopolitical developments, market conditions, and trade policies as factors that continue to make TAPI an attractive acquisition target. For now, TAPI operates as a standalone unit within Teva, providing both API and CDMO services to the pharmaceutical industry while under the divestment process.